Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Voyager Therapeutics Inc VYGR

Healthcare Biotechnology
Voyager Therapeutics, Inc. is a biotechnology company focused on advancing neurogenetic medicines. The Company’s pipeline includes programs for Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple other diseases of the central nervous system. Many of its programs are derived from its TRACER AAV capsid discovery platform, which is used to generate novel... see more

Recent & Breaking News (NDAQ:VYGR)

Voyager Therapeutics to Present Preclinical Data from its Vectorized anti-HER2 Antibody Program and a Novel AAV5-Derived TRACER(TM) Capsid at the 25th American Society of Gene and Cell Therapy Annual Meeting

GlobeNewswire May 16, 2022

Voyager Therapeutics Reports First Quarter 2022 Financial and Operating Results

GlobeNewswire May 4, 2022

Voyager Therapeutics Announces Multiple Data Presentations at the American Society of Gene and Cell Therapy 2022 Annual Meeting

GlobeNewswire May 3, 2022

Voyager Therapeutics Appoints Alfred W. Sandrock, Jr., M.D., Ph.D., as Chief Executive Officer

GlobeNewswire March 22, 2022

Voyager Therapeutics Reports Fourth Quarter and Full Year 2021 Financial and Operating Results

GlobeNewswire March 8, 2022

Voyager Therapeutics Announces License Option Agreement with Novartis for Target-Specific Access to Next-Generation TRACER(TM) AAV Capsids for Gene Therapy Programs

GlobeNewswire March 8, 2022

Voyager Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire February 10, 2022

Alfred W. Sandrock, Jr., M.D., Ph.D. Appointed to Voyager Therapeutics' Board of Directors and Newly Formed Executive Committee

GlobeNewswire February 3, 2022

Voyager Therapeutics Announces Positive Preclinical Data from New Vectorized anti-HER2 Antibody Program at the 26th Society for Neuro-Oncology Annual Meeting

GlobeNewswire November 19, 2021

Voyager Therapeutics to Present Preclinical Data from Vectorized Antibody Program at the 26th Society for Neuro-Oncology Annual Meeting

GlobeNewswire November 16, 2021

Voyager Therapeutics Reports Third Quarter 2021 Financial and Operating Results

GlobeNewswire November 2, 2021

Voyager Therapeutics Presents Positive Preclinical Data Supporting CNS-Directed GBA1 Gene Therapy at Virtual Congress of the European Society of Gene and Cell Therapy

GlobeNewswire October 20, 2021

Voyager Therapeutics Announces License Option Agreement with Pfizer for Next-Generation TRACERᵀᴹ AAV Capsids to Enable Neurologic and Cardiovascular Gene Therapy Programs

GlobeNewswire October 6, 2021

Voyager Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire September 2, 2021

Voyager Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire August 10, 2021

Voyager Therapeutics Transforms Pipeline and Increases Investment in Next-Generation TRACER(TM) AAV Capsid and Vectorized Antibody Platform Technologies

GlobeNewswire August 9, 2021

Voyager Therapeutics Announces Strategic Shift and Leadership Transitions

GlobeNewswire May 19, 2021

Voyager Therapeutics Presents New Preclinical Data Showing Reduction of Pathological Tau with Vectorized Anti-Tau Antibody

GlobeNewswire May 12, 2021

Voyager Therapeutics' Novel Capsids Demonstrate Robust Delivery Across the Blood Brain Barrier, Widespread CNS Transduction in Non-Human Primates

GlobeNewswire May 11, 2021

Voyager Therapeutics Announces First Quarter 2021 Financial Results and Corporate Updates

GlobeNewswire May 10, 2021